Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer
详细信息 查看全文
- 作者：Alison M. Kurimchak1 ; Claude Shelton1 ; Kelly E. Duncan1 ; Katherine J. Johnson1 ; Jennifer Brown1 ; Shane O&rsquo ; Brien2 ; Rashid Gabbasov2 ; 4 ; Lauren S. Fink1 ; Yuesheng Li1 ; Nicole Lounsbury3 ; Magid Abou-Gharbia3 ; Wayne E. Childers3 ; Denise C. Connolly2 ; Jonathan Chernoff1 ; Jeffrey R. Peterson1 ; James S. Duncan1 ; james.duncan2@fccc.edu" class="auth_mail" title="E-mail the corresponding author
- 刊名：Cell Reports
- 出版年：2016
- 出版时间：2 August 2016
- 年：2016
- 卷：16
- 期：5
- 页码：1273-1286
- 全文大小：6922 K
文摘
- •
Inhibition of BET proteins reprograms kinome activity in ovarian cancer cells
- •
Receptor tyrosine kinase activation overcomes BET inhibition, causing resistance
- •
Elevated PI3K/ERK activity stabilizes MYC/FOSL1 proteins in JQ1-resistant cells
- •
Co-targeting BET proteins and RTK or PI3K signaling enhances BET inhibitor therapy